The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease

Lancet Neurology

Volumn 1, Issue 5, 2002, Pages 279-284

  Aisen, Paul S ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; CELECOXIB; COMPLEMENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IBUPROFEN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; NCX 2216; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; ROFECOXIB; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; GENETIC ANALYSIS; HUMAN; INFLAMMATION; LOW DRUG DOSE; MEDICAL RESEARCH; MICROGLIA; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK MANAGEMENT; SIDE EFFECT; ANIMAL; ENCEPHALITIS; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; OXIDATIVE STRESS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTI-INFLAMMATORY AGENTS; ENCEPHALITIS; HUMANS; MICROGLIA; OXIDATIVE STRESS;

EID: 0141453824     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(02)00133-3     Document Type: Review

References (73)

1. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 81:2001;741-766.
2. Roberds S.L., Anderson J., Basi G., et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet. 10:2001;1317-1324.
3. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
4. Morgan D., Diamond D.M., Gottschall P.E., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
5. Iwata N., Tsubuki S., Takaki Y., et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 6:2000;143-150.
6. Hama E., Shirotani K., Masumoto H., Sekine-Aizawa Y., Aizawa H., Saido T.C. Clearance of extracellular and cell-associated amyloid beta peptide through viral expression of neprilysin in primary neurons. J Biochem (Tokyo). 130:2001;721-726.
7. Kurochkin I.V., Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett. 345:1994;33-37.
8. Qiu W.Q., Walsh D.M., Ye Z., et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta- protein by degradation. J Biol Chem. 273:1998;32730-32738.
9. Aisen P.S., Davis K.L. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 48:(suppl 6):1997;S35-S41.
10. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry. 151:1994;1105-1113.
11. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21:2000;383-421.
12. Fagarasan M.O., Aisen P.S. Il-1 and anti-inflammatory drugs modulate Abeta cytotoxicity in PC12 cells. Brain Res. 723:1996;231-234.
13. Campbell I.L., Abraham C.R., Masliah E., et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA. 90:1993;10061-10065.
14. Mrak R.E., Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 22:2001;903-908.
15. Vandenabeele P., Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol Today. 12:1991;217-219.
16. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 56:1989;259-262.
17. Goldgaber D., Harris H., Hla T., et al. Interleukin-1 regulates synthesis of amyloid beta protein precursor mRNA in human endothelial cell. Proc Natl Acad Sci USA. 86:1989;7606-7610.
18. Oda T., Lehrer-Graiwer J., Finch C.E., Pasinetti G.M. Complement and beta-amyloid neurotoxicity in vitro: a model for Alzheimer disease, Alzheimer. s Res. 1:1995;29-34.
19. Webster S., Lue L.F., Brachova L., et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging. 18:1997;415-421.
20. Eikelenboom P., Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 17:1996;673-680.
21. Giulian D. Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet. 65:1999;13-18.
22. Wyss-Coray T., Lin C., Yan F., et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 7:2001;612-618.
23. Kakimura J., Kitamura Y., Takata K., et al. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J. 16:2002;601-603.
24. Jantzen P.T., Connor K.E., DiCarlo G., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drugs in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 22:2002;2246-2254.
25. Hensley K., Maidt M.L., Yu Z.Q., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 18:1998;8126-8132.
26. Williamson K.S., Prasad Gabbita S., Mou S., et al. The nitration product 5-nitro-gamma-tocopherol is increased in the Alzheimer brain. Nitric Oxide. 6:2002;221-227.
27. Vitek M.P., Snell J., Dawson H., Colton C.A. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem Biophys Res Commun. 240:1997;391-394.
28. Mackenzie I.R.A., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986-990.
29. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
30. Stewart W.F., Kawas C., Corrada M., Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
31. Anthony J.C., Breitner J.C., Zandi P.P., et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology. 54:2000;2066-2071.
32. Broe G.A., Grayson D.A., Creasey H.M., et al. Anti-inflammatory drugs protect against alzheimer disease at low doses. Arch Neurol. 57:2000;1586-1591.
33. in t' Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 345:2001;1515-1521.
34. Henderson A.S., Jorm A.F., Christensen H., Jacomb P.A., Korten A.E. Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry. 12:1997;926-930.
35. Beard C.M., Waring S.C., O'Brien P.C., Kurland L.T., Kokmen E. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, through 1984. Mayo Clin Proc ; 73. 1998:1980;951-955.
36. Wolfson C., Perrault A., Moride Y., Esdaile J.M., Abenhaim L., Momoli F. A case-control analysis of nonsteroidal anti-inflammatory drugs and Alzheimer's disease: are they protective? Neuroepidemiology. 21:2002;81-86.
37. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
38. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:1999;197-201.
39. Aisen P.S., Davis K.L., Berg J.D., et al. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study. Neurology. 54:2000;588-593.
40. Sainati SM, Ingram DM, Talwalker S, Geis GS. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden, 2000: 180.
41. Van Gool W.A., Weinstein H.C., Scheltens P.K., Walstra G.J. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 358:2001;455-460.
42. Prevention of Alzheimer's and cognitive decline: grant 7U01AG015477-03.http://commons.cit.nih.gov/crisp3/Crisp_Query.Generate_Screen, accessed August 2002.
43. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychiatry. 141:1984;1356-1364.
44. Morris J.C., Ernesto C., Schafer K., et al. Clinical Dementia Rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology. 48:1997;1508-1510.
45. Teunisse S., Bollen A.E., van Gool W.A., Walstra G.J. Dementia and subnormal levels of vitamin B12: effects of replacement therapy on dementia. J Neurol. 243:1996;522-529.
46. Aisen P.S., Marin D., Altstiel L., et al. A pilot study of prednisone in Alzheimer's disease. Dementia. 7:1996;201-206.
47. Fagarasan M.O., Sevilla D., Baruch B., Santoro J., Marin D., Aisen P.S. Plasma C3a levels in Alzheimer's disease, Alzheimer. s Research. 3:1997;137-140.
48. Aisen P.S. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurol Scand Suppl. 176:2000;85-89.
49. Giulian D., Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol. 27:1990;33-42.
50. Sperber K., Quraishi H., Kalb T.H., Panja A., Stecher V., Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: Inhibition of interleukin 1 alpha and IL-6 in human monocytes and T cells. J Rheumatol. 20:1993;803-808.
51. Vane J.R., Botting R.M. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 44:1995;1-10.
52. Planas A.M., Soriano M.A., Rodriguez-Farr E., Ferrer I. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett. 200:1995;187-190.
53. Tocco G., Freire M.J., Schreiber S.S., Sakhi S.H., Aisen P.S., Pasinetti G.M. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp Neurol. 144:1997;339-349.
54. Pasinetti G.M., Aisen P.S. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87:1998;319-324.
55. Matsuoka Y., Picciano M., Malester B., et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 158:2001;1345-1354.
56. Hewett S.J., Uliasz T.F., Vidwans A.S., Hewett J.A. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J Pharmacol Exp Ther. 293:2000;417-425.
57. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflam mation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res. 134:2000;58-65.
58. Kunz T., Oliw E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate- induced cell death in the rat hippocampus. Eur J Neurosci. 13:2001;569-575.
59. Araki E., Forster C., Dubinsky J.M., Ross M.E., Iadecola C. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke. 32:2001;2370-2375.
60. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830:1999;226-236.
61. Ho L., Purohit D., Haroutunian V., et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 58:2001;487-492.
62. Chang J.W., Coleman P.D., O'Banion M.K. Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging. 17:1996;801-808.
63. Lukiw W.J., Bazan N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res. 50:1997;937-945.
64. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
65. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci. 20:2000;558-567.
66. Leszek J., Gasiorowski K. Therapeutic efficacy of cyclophosphamide in Alzheimer's disease, Alzheimer. s Research. 2:1996;43-46.
67. Jarvis B., Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs. 57:1999;945-966.
68. Valle E., Gross M., Bickston S.J. Infliximab. Expert Opin Pharmacother. 2:2001;1015-1025.
69. Perry R.T., Collins J.S., Wiener H., Acton R., Go R.C. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 22:2001;873-883.
70. Tan J., Town T., Paris D., et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 286:1999;2352-2355.
71. Tan J., Town T., Mori T., et al. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci. 20:2000;7587-7594.
72. Guan Z.H., Buckman S.Y., Miller B.W., Springer L.D., Morrison A.R. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem. 273:1998;28670-28676.
73. Tenner A.J. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 22:2001;849-861.